Diabetologia

pp 1–14 | Cite as

Protective role of the ELOVL2/docosahexaenoic acid axis in glucolipotoxicity-induced apoptosis in rodent beta cells and human islets

  • Lara Bellini
  • Mélanie Campana
  • Claude Rouch
  • Marta Chacinska
  • Marco Bugliani
  • Kelly Meneyrol
  • Isabelle Hainault
  • Véronique Lenoir
  • Jessica Denom
  • Julien Véret
  • Nadim Kassis
  • Bernard Thorens
  • Mark Ibberson
  • Piero Marchetti
  • Agnieszka Blachnio-Zabielska
  • Céline Cruciani-Guglielmacci
  • Carina Prip-Buus
  • Christophe Magnan
  • Hervé Le Stunff
Article

Abstract

Aims/hypothesis

Dietary n-3 polyunsaturated fatty acids, especially docosahexaenoic acid (DHA), are known to influence glucose homeostasis. We recently showed that Elovl2 expression in beta cells, which regulates synthesis of endogenous DHA, was associated with glucose tolerance and played a key role in insulin secretion. The present study aimed to examine the role of the very long chain fatty acid elongase 2 (ELOVL2)/DHA axis on the adverse effects of palmitate with high glucose, a condition defined as glucolipotoxicity, on beta cells.

Methods

We detected ELOVL2 in INS-1 beta cells and mouse and human islets using quantitative PCR and western blotting. Downregulation and adenoviral overexpression of Elovl2 was carried out in beta cells. Ceramide and diacylglycerol levels were determined by radio-enzymatic assay and lipidomics. Apoptosis was quantified using caspase-3 assays and poly (ADP-ribose) polymerase cleavage. Palmitate oxidation and esterification were determined by [U-14C]palmitate labelling.

Results

We found that glucolipotoxicity decreased ELOVL2 content in rodent and human beta cells. Downregulation of ELOVL2 drastically potentiated beta cell apoptosis induced by glucolipotoxicity, whereas adenoviral Elovl2 overexpression and supplementation with DHA partially inhibited glucolipotoxicity-induced cell death in rodent and human beta cells. Inhibition of beta cell apoptosis by the ELOVL2/DHA axis was associated with a decrease in ceramide accumulation. However, the ELOVL2/DHA axis was unable to directly alter ceramide synthesis or metabolism. By contrast, DHA increased palmitate oxidation but did not affect its esterification. Pharmacological inhibition of AMP-activated protein kinase and etomoxir, an inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in fatty acid β-oxidation, attenuated the protective effect of the ELOVL2/DHA axis during glucolipotoxicity. Downregulation of CPT1 also counteracted the anti-apoptotic action of the ELOVL2/DHA axis. By contrast, a mutated active form of Cpt1 inhibited glucolipotoxicity-induced beta cell apoptosis when ELOVL2 was downregulated.

Conclusions/interpretation

Our results identify ELOVL2 as a critical pro-survival enzyme for preventing beta cell death and dysfunction induced by glucolipotoxicity, notably by favouring palmitate oxidation in mitochondria through a CPT1-dependent mechanism.

Keywords

AMPK Apoptosis Ceramide DHA ELOVL2 Glucolipotoxicity Mitochondrial β-oxidation Pancreatic beta cells Type 2 diabetes 

Abbreviations

ACC

Acetyl-CoA carboxylase

AICAR

5-Aminoimidazole-4-carboxamide ribonucleotide

AMPK

AMP-activated protein kinase

ASP

Acid-soluble products

CPT1

Carnitine palmitoyltransferase 1

DHA

Docosahexaenoic acid

ELOVL2

Very long chain fatty acid elongase 2

GPR120

G-protein coupled receptor 120

MUFA

Monounsaturated fatty acid

PARP

Poly (ADP-ribose) polymerase

PPMP

dl-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol

PUFA

Polyunsaturated fatty acid

siRNA

Small interfering RNA

Notes

Acknowledgements

The authors thank C. K. Ng, University College Dublin, Belfield, Ireland, for help with preparing the manuscript.

Contribution statement

HLS and LB contributed to the study concept and design, and to the analysis and interpretation of the data. LB, MCa, CR, NK, JV, KM and JD contributed to the acquisition of the data on caspase activity and the western blot experiments. LB and NK contributed to the acquisition and interpretation of the data from quantitative PCR experiments. LB and IH contributed to generate Elovl2 adenoviruses and interpretation of data using them. VL and CP-B contributed to the acquisition and interpretation of the data on [U-14C]palmitate metabolism. MB contributed to the preparation of human islets and analysis of the data. MCh and AB-Z performed and analysed the lipidomic data. CM, CC-G, PM, MI and BT contributed to the analysis of the data. HLS, LB and CM wrote/edited the manuscript with contributions from CP-B, CC-G, MI, PM and BT. HLS is responsible for the integrity of the work as a whole. All authors revised the article and approved the final version.

Funding

This project was supported by grants from the Centre National de la Recherche Scientifique (CNRS), the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 155005 (IMIDIA), and the Agence Nationale de la Recherche (ANR PRCI-15-CE14-0027-01 BetaDiamark). LB received a doctoral fellowship supported by IMIDIA-ENSO. MCa received a doctoral fellowship from the Cardiovasculaire – Obésité – Rein – Diabète – Domaine d’Intérêt Majeur (CORDDIM), Ile de France. JV was supported by a postdoctoral fellowship from Université Paris Diderot.

Duality of interest

All authors declare that they have no duality of interest associated with this manuscript. The study sponsor was not involved in the design of the study, interpretation of the data or writing of the report.

Supplementary material

125_2018_4629_MOESM1_ESM.pdf (574 kb)
ESM (PDF 573 kb)

References

  1. 1.
    Nolan CJ, Leahy JL, Delghingaro-Augusto V et al (2006) Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia 49:2120–2130CrossRefPubMedGoogle Scholar
  2. 2.
    Prentki M (2006) Islet cell failure in type 2 diabetes. J Clin Invest 116:1802–1812CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Pick A, Clark J, Kubstrup C et al (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358–364CrossRefPubMedGoogle Scholar
  4. 4.
    Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738–744CrossRefPubMedGoogle Scholar
  5. 5.
    Shimabukuro M, Higa M, Zhou YT et al (1998) Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 273:32487–32490CrossRefPubMedGoogle Scholar
  6. 6.
    El-Assaad W, Buteau J, Peyot M-L et al (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144:4154–4163CrossRefPubMedGoogle Scholar
  7. 7.
    Maedler K, Spinas GA, Lehmann R et al (2001) Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50:1683–1690CrossRefPubMedGoogle Scholar
  8. 8.
    Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95:2498–2502CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Prentki M, Joly E, El-Assaad W, Roduit R (2002) Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 51(Suppl 3):S405–S413CrossRefPubMedGoogle Scholar
  10. 10.
    Kelpe CL, Moore PC, Parazzoli SD et al (2003) Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J Biol Chem 278:30015–30021CrossRefPubMedGoogle Scholar
  11. 11.
    El-Assaad W, Joly E, Barbeau A et al (2010) Glucolipotoxicity alters lipid partitioning and causes mitochondrial dysfunction, cholesterol, and ceramide deposition and reactive oxygen species production in INS832/13 ss-cells. Endocrinology 151:3061–3073CrossRefPubMedGoogle Scholar
  12. 12.
    Maedler K, Oberholzer J, Bucher P et al (2003) Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52:726–733CrossRefPubMedGoogle Scholar
  13. 13.
    Bhaswant M, Poudyal H, Brown L (2015) Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. J Nutr Biochem 26:571–584CrossRefPubMedGoogle Scholar
  14. 14.
    Jump DB, Clarke SD (1999) Regulation of gene expression by dietary fat. Annu Rev Nutr 19:63–90CrossRefPubMedGoogle Scholar
  15. 15.
    Sekiya M, Yahagi N, Matsuzaka T et al (2003) Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38:1529–1539CrossRefPubMedGoogle Scholar
  16. 16.
    González-Périz A, Horrillo R, Ferré N et al (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 23:1946–1957CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Oosterveer MH, van Dijk TH, Tietge UJF et al (2009) High fat feeding induces hepatic fatty acid elongation in mice. PLoS One 4:e6066CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pauter AM, Olsson P, Asadi A et al (2014) Elovl2 ablation demonstrates that systemic DHA is endogenously produced and is essential for lipid homeostasis in mice. J Lipid Res 55:718–728CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Cruciani-Guglielmacci C, Bellini L, Denom J et al (2017) Molecular phenotyping of multiple mouse strains under metabolic challenge uncovers a role for Elovl2 in glucose-induced insulin secretion. Mol Metab 6:340–351CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Véret J, Coant N, Berdyshev EV et al (2011) Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in glucolipotoxicity-induced apoptosis of INS-1 β-cells. Biochem J 438:177–189CrossRefPubMedGoogle Scholar
  21. 21.
    Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917CrossRefPubMedGoogle Scholar
  22. 22.
    Berdyshev EV, Gorshkova IA, Usatyuk P et al (2006) De novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells. Cell Signal 18:1779–1792CrossRefPubMedGoogle Scholar
  23. 23.
    Akkaoui M, Cohen I, Esnous C et al (2009) Modulation of the hepatic malonyl-CoA–carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. Biochem J 420:429–438CrossRefPubMedGoogle Scholar
  24. 24.
    Bellini L, Campana M, Mahfouz R et al (2015) Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes. Expert Opin Ther Targets 19:1037–1050CrossRefPubMedGoogle Scholar
  25. 25.
    Gjoni E, Brioschi L, Cinque A et al (2014) Glucolipotoxicity impairs ceramide flow from the endoplasmic reticulum to the Golgi apparatus in INS-1 β-cells. PLoS One 9:e110875CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lima S, Milstien S, Spiegel S (2014) A real-time high-throughput fluorescence assay for sphingosine kinases. J Lipid Res 55:1525–1530CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Choi S-E, Jung I-R, Lee Y-J et al (2011) Stimulation of lipogenesis as well as fatty acid oxidation protects against palmitate-induced INS-1 beta-cell death. Endocrinology 152:816–827CrossRefPubMedGoogle Scholar
  28. 28.
    Cnop M, Hannaert JC, Hoorens A et al (2001) Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 50:1771–1777CrossRefPubMedGoogle Scholar
  29. 29.
    Prentki M, Madiraju SRM (2012) Glycerolipid/free fatty acid cycle and islet β-cell function in health, obesity and diabetes. Mol Cell Endocrinol 353:88–100CrossRefPubMedGoogle Scholar
  30. 30.
    Hardie DG, Pan DA (2002) Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 30:1064–1070CrossRefPubMedGoogle Scholar
  31. 31.
    Henique C, Mansouri A, Vavrova E et al (2015) Increasing mitochondrial muscle fatty acid oxidation induces skeletal muscle remodeling toward an oxidative phenotype. FASEB J 29:2473–2483CrossRefPubMedGoogle Scholar
  32. 32.
    Biden TJ, Boslem E, Chu KY, Sue N (2014) Lipotoxic endoplasmic reticulum stress, β cell failure, and type 2 diabetes mellitus. Trends Endocrinol Metab 25:389–398CrossRefPubMedGoogle Scholar
  33. 33.
    Kato T, Shimano H, Yamamoto T et al (2008) Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 57:2382–2392CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Taneera J, Lang S, Sharma A et al (2012) A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab 16:122–134CrossRefPubMedGoogle Scholar
  35. 35.
    Manukyan L, Ubhayasekera SJKA, Bergquist J et al (2015) Palmitate-induced impairments of β-cell function are linked with generation of specific ceramide species via acylation of sphingosine. Endocrinology 156:802–812CrossRefPubMedGoogle Scholar
  36. 36.
    Nolan CJ, Larter CZ (2009) Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it? J Gastroenterol Hepatol 24:703–706CrossRefPubMedGoogle Scholar
  37. 37.
    Jelenik T, Rossmeisl M, Kuda O et al (2010) AMP-activated protein kinase α2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes 59:2737–2746CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Lara Bellini
    • 1
  • Mélanie Campana
    • 1
  • Claude Rouch
    • 1
  • Marta Chacinska
    • 2
    • 3
  • Marco Bugliani
    • 4
  • Kelly Meneyrol
    • 1
  • Isabelle Hainault
    • 5
  • Véronique Lenoir
    • 6
    • 7
    • 8
  • Jessica Denom
    • 1
  • Julien Véret
    • 1
  • Nadim Kassis
    • 1
  • Bernard Thorens
    • 9
  • Mark Ibberson
    • 10
  • Piero Marchetti
    • 4
  • Agnieszka Blachnio-Zabielska
    • 2
    • 3
  • Céline Cruciani-Guglielmacci
    • 1
  • Carina Prip-Buus
    • 6
    • 7
    • 8
  • Christophe Magnan
    • 1
  • Hervé Le Stunff
    • 1
    • 11
  1. 1.Unité Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, Équipe Régulation de la glycémie par le système nerveux central, Université Paris DiderotParis CEDEX 13France
  2. 2.Department of PhysiologyMedical University of BialystokBialystokPoland
  3. 3.Department of Hygiene, Epidemiology and Metabolic DisordersMedical University of BialystokBialystokPoland
  4. 4.Department of Clinical and Experimental Medicine, Islet LaboratoryUniversity of PisaPisaItaly
  5. 5.Inserm, UMR 1138, Centre de Recherche des CordeliersParisFrance
  6. 6.Inserm U1016, Institut CochinParisFrance
  7. 7.CNRS UMR 8104ParisFrance
  8. 8.Université Paris Descartes, Sorbonne Paris CitéParisFrance
  9. 9.Centre for Integrative Genomics, University of LausanneLausanneSwitzerland
  10. 10.Vital-IT Group, SIB Swiss Institute of BioinformaticsLausanneSwitzerland
  11. 11.Université Paris-Sud, Paris-Saclay Institute of Neuroscience, CNRS UMR 9197OrsayFrance

Personalised recommendations